Malta - Ingliż - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - exemestane - film-coated tablet - exemestane 25 mg - endocrine therapy

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - exemestane, quantity: 25 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; sodium starch glycollate type a; hypromellose; mannitol; microcrystalline cellulose; magnesium stearate; crospovidone; polysorbate 80; titanium dioxide; macrogol 400 - exemestane is indicated for the sequential adjuvant treatment of oestrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy. . exemestane is indicated for the treatment of oestrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy.

Stati Uniti - Ingliż - NLM (National Library of Medicine)

pharmacia & upjohn company llc - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane 25 mg - aromasin is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to aromasin for completion of a total of five consecutive years of adjuvant hormonal therapy [see clinical studies (14.1)]. aromasin is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see clinical studies (14.2)]. aromasin is contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients. risk summary based on findings in animal studies and its mechanism of action, aromasin can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited human data from case reports are insufficient to inform a drug-associated risk. in animal reproduction studies, administration of exemestane to pregnant rats and rabbits caused increased incidence of abortions, embryo-fetal toxicit

Stati Uniti - Ingliż - NLM (National Library of Medicine)

physicians total care, inc. - exemestane (unii: ny22hmq4bx) (exemestane - unii:ny22hmq4bx) - exemestane 25 mg - aromasin is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to aromasin for completion of a total of five consecutive years of adjuvant hormonal therapy. aromasin is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. aromasin tablets are contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - exemestane -

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - exemestane, quantity: 25 mg - tablet, sugar coated - excipient ingredients: silicon dioxide; crospovidone; hypromellose; magnesium carbonate hydrate; mannitol; microcrystalline cellulose; methyl hydroxybenzoate; macrogol 6000; polysorbate 80; polyvinyl alcohol; sodium starch glycollate; sucrose; titanium dioxide; cetyl esters wax; purified talc; carnauba wax; shellac; iron oxide black; magnesium stearate; purified water; sorbic acid; dimeticone 100; dimeticonol; benzoic acid - aromasin is indicated for the sequential adjuvant treatment of estrogen receptor-positive early breast cancer in post-menopausal women who have received prior adjuvant tamoxifen therapy.,aromasin is indicated for the treatment of estrogen receptor-positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-estrogen therapy.

Armenja - Ingliż - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

accord healthcare limited - exemestane - tablets film-coated - 25mg

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - exemestane, quantity: 25 mg - tablet, sugar coated - excipient ingredients: purified talc; sucrose; titanium dioxide; magnesium stearate; colloidal anhydrous silica; acacia; crospovidone; microcrystalline cellulose; mannitol; polysorbate 80; ethanol; shellac; white beeswax; carnauba wax - exemestane is indicated for:,? sequential adjuvant treatment of estrogen receptor positive early breast cancer in postmenopausal women who have received prior adjuvant tamoxifen therapy.,? treatment of estrogen receptor positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following antiestrogen therapy.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - exemestane, quantity: 25 mg - tablet, sugar coated - excipient ingredients: purified talc; microcrystalline cellulose; colloidal anhydrous silica; acacia; mannitol; polysorbate 80; magnesium stearate; sucrose; titanium dioxide; crospovidone; ethanol; shellac; white beeswax; carnauba wax - sequential adjuvant treatment of oestrogen receptor positive early breast cancer in postmenopausal women who have received prior adjuvant tamoxifen therapy.,treatment of oestrogen receptor positive advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following antioestrogen therapy.

Belġju - Ingliż - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare b.v. - exemestane 25 mg - film-coated tablet - 25 mg - exemestane 25 mg - exemestane